Literature DB >> 7195152

Spironolactone bodies in aldosteronomas and in the attached adrenals. Enzyme histochemical study of 19 cases of primary aldosteronism and a case of aldosteronism due to bilateral diffuse hyperplasia of the zona glomerulosa.

M Aiba, H Suzuki, K Kageyama, M Murai, H Tazaki, O Abe, T Saruta.   

Abstract

The formation of spironolactone (S) bodies, eosinophilic laminated cytoplasmic inclusions, is induced in the aldosterone-producing cells of the human adrenal cortex after the administration of spironolactone. The aim of this study was to define the enzyme histochemical characteristics of S bodies, S-body-containing cells, and the apparently hyperplastic zona glomerulosa (zG) of adrenal tissues attached to aldosteronomas. S bodies were found in 14 of 19 aldosteronomas, in 10 of 19 adrenal tissues attached to aldosteronomas, and in the adrenal tissues in a patient with aldosteronism due to bilateral diffuse zG hyperplasia. The S bodies themselves exhibited most intense 3 beta-hydroxysteroid dehydrogenase (3 beta HSD) activity but did not exhibit glucose-6-phosphate dehydrogenase (G6PD), NADP-dependent isocitrate dehydrogenase (NADP-ICDH), or succinate dehydrogenase (SDH) activity, confirming histochemically the origin of S bodies in the smooth endoplasmic reticulum. In two adenomas, S bodies were found to be surrounded by reaction products of acid hydrolase but were not found in the other adenomas and the remaining adrenal tissues. S-body-containing cells, irrespective of being neoplastic or not, showed enhanced 3 beta HSD, G6PD, and NADP-ICDH activity and weak SDH activity (Type I pattern of enzyme activity). Though zG was hyperplastic in most of the adrenal tissues attached to the adenomas, zG cells that did not contain S bodies showed the opposite pattern (Type II pattern) of enzyme activity (ie, weak 3 beta HSD, G6PD, and NADP-ICDH activity and intense SDH activity), in contrast to those in the adrenal tissues in a patient with aldosteronism due to bilateral diffuse zG hyperplasia (which showed the Type I pattern). The results are consistent with the view that hyperplastic zG cells, except S-body-containing cells, in the case of aldosteronoma are not hyperfunctioning. The latter cells may have enhanced but possibly abortive steroidogenic activity.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7195152      PMCID: PMC1903848     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  19 in total

1.  HISTOCHEMICAL DEMONSTRATION OF N-ACETYL-BETA-GLUCOSAMINIDASE EMPLOYING NAPHTHOL AS-BI N-ACETYL-BETA -GLUCOSAMINIDE AS SUBSTRATE.

Authors:  M HAYASHI
Journal:  J Histochem Cytochem       Date:  1965 May-Jun       Impact factor: 2.479

2.  Microscopic histochemical demonstration of steroid-3 beta-ol dehydrogenase in tissue sections.

Authors:  L W WATTENBERG
Journal:  J Histochem Cytochem       Date:  1958-07       Impact factor: 2.479

3.  Spironolactone bodies in an adrenal adenoma.

Authors:  S S Shrago; J Waisman; P H Cooper
Journal:  Arch Pathol       Date:  1975-08

4.  Spironolactone-induced inhibition of aldosterone biosynthesis in primary aldosteronism: morphological and functional studies.

Authors:  J W Conn; D L Hinerman
Journal:  Metabolism       Date:  1977-12       Impact factor: 8.694

5.  Spironolactone inclusions in an aldosteronoma.

Authors:  D R Cain; R L Van de Velde; S J Shapiro
Journal:  Am J Clin Pathol       Date:  1974-03       Impact factor: 2.493

6.  Reduced aldosterone secretion during spironolactone treatment in primary aldosteronism: report of a case.

Authors:  J A Sundsfjord; P Marton; H Jorgensen; A Aakvaag
Journal:  J Clin Endocrinol Metab       Date:  1974-10       Impact factor: 5.958

7.  The effect of saluretics and spironolactone on aldosterone production and electrolyte excretion in man.

Authors:  H C Erbler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

8.  Histochemical comparison of oxidative enzymes in adrenal glands of mammals.

Authors:  K Okano; K Matsumoto; T Koizumi; T Mizushima; M Mori
Journal:  Histochemie       Date:  1965-03-05

9.  Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria.

Authors:  S C Cheng; K Suzuki; W Sadee; B W Harding
Journal:  Endocrinology       Date:  1976-10       Impact factor: 4.736

10.  Enzyme histochemical and electron microscopic study of a virilizing adrenocortical adenoma.

Authors:  M Aiba; T Kameya; H Suzuki; H Nakamura; Y Mizuno; T Kanno
Journal:  Acta Pathol Jpn       Date:  1978-07
View more
  6 in total

1.  Alteration of subcapsular adrenocortical zonation in humans with aging: the progenitor zone predominates over the previously well-developed zona glomerulosa after 40 years of age.

Authors:  Motohiko Aiba; Mariko Fujibayashi
Journal:  J Histochem Cytochem       Date:  2011-03-16       Impact factor: 2.479

2.  Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis.

Authors:  P Ye; T Yamashita; D M Pollock; H Sasano; W E Rainey
Journal:  Horm Metab Res       Date:  2008-09-25       Impact factor: 2.936

3.  The value of losartan suppression test in the confirmatory diagnosis of primary aldosteronism in patients over 50 years old.

Authors:  Chin-Chi Kuo; Poojitha Balakrishnan; Yenh-Chen Hsein; Vin-Cent Wu; Shih-Chieh Jeff Chueh; Yung-Ming Chen; Kwan-Dun Wu; Ming-Jiuh Wang
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2014-07-16       Impact factor: 1.636

4.  Histopathological diagnosis and prognostic factors in adrenocortical carcinoma.

Authors:  Motohiko Aiba; Mariko Fujibayashi
Journal:  Endocr Pathol       Date:  2005       Impact factor: 4.056

5.  Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology.

Authors:  Sofia S Pereira; Liliana Carvalho; Madalena M Costa; Armindo Melo; Isabel M P L V O Ferreira; Celso E Gomez-Sanchez; Mariana P Monteiro; Gavin Vinson; Duarte Pignatelli
Journal:  Biomedicines       Date:  2021-04-20

6.  Adrenal gland inclusions in patients treated with aldosterone antagonists (Spironolactone/Eplerenone): incidence, morphology, and ultrastructural findings.

Authors:  Kishan A Patel; Edward P Calomeni; Tibor Nadasdy; Debra L Zynger
Journal:  Diagn Pathol       Date:  2014-08-09       Impact factor: 2.644

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.